NASDAQ · CHRS
Healthcare · Biotechnology
$1.42
Up+$0.10 (+7.58%)
Updated Aug 22, 2026, 2:43 AM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
CHRS closed at $1.42 after 21 trading sessions, up 0.71% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $1.32 | $1.44 | $1.315 | $1.42 | 1.57M |
| Aug 20, 2026 | $1.31 | $1.34 | $1.27 | $1.32 | 740.19K |
| Aug 19, 2026 | $1.379 | $1.405 | $1.295 | $1.33 | 3.04M |
| Aug 18, 2026 | $1.26 | $1.36 | $1.22 | $1.34 | 3.48M |
| Aug 17, 2026 | $1.20 | $1.2001 | $1.13 | $1.15 | 1.26M |
| Aug 14, 2026 | $1.16 | $1.205 | $1.14 | $1.20 | 648.33K |
| Aug 13, 2026 | $1.18 | $1.195 | $1.13 | $1.14 | 1.06M |
| Aug 12, 2026 | $1.21 | $1.2462 | $1.17 | $1.17 | 1.16M |
| Aug 11, 2026 | $1.25 | $1.2599 | $1.18 | $1.21 | 968.34K |
| Aug 10, 2026 | $1.33 | $1.34 | $1.23 | $1.24 | 978.46K |
| Aug 7, 2026 | $1.27 | $1.40 | $1.24 | $1.27 | 1.6M |
| Aug 6, 2026 | $1.385 | $1.455 | $1.131 | $1.265 | 3.72M |
| Aug 5, 2026 | $1.48 | $1.525 | $1.435 | $1.45 | 999.32K |
| Aug 4, 2026 | $1.43 | $1.50 | $1.43 | $1.48 | 617.72K |
| Aug 3, 2026 | $1.42 | $1.4591 | $1.414 | $1.44 | 477.28K |
| Jul 31, 2026 | $1.48 | $1.48 | $1.40 | $1.41 | 437.18K |
| Jul 30, 2026 | $1.42 | $1.485 | $1.415 | $1.47 | 509.55K |
| Jul 29, 2026 | $1.44 | $1.475 | $1.40 | $1.41 | 570.98K |
| Jul 28, 2026 | $1.46 | $1.47 | $1.415 | $1.44 | 387.63K |
| Jul 27, 2026 | $1.46 | $1.495 | $1.44 | $1.46 | 456.66K |
| Jul 24, 2026 | $1.44 | $1.445 | $1.395 | $1.41 | 446.4K |
The latest Smart Investors Daily articles mentioning CHRS.
CHRS research
Company profile and research snapshot.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | Guggenheim | Buy | — |
| May 11, 2026 | Guggenheim | Buy | — |
| Jan 22, 2026 | Oppenheimer | Outperform | — |
| Sep 4, 2025 | Maxim Group | Buy | — |
| Apr 29, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Aug 19, 2026
Coherus Oncology Hold: ahead of key 2H 2026 data readouts for tagmokitug/casdozokitug; Q4 2026 HCC catalyst, cash/dilution risk. Click for more on CHRS stock.
Benzinga · Aug 17, 2026
Coherus Oncology, Inc. (NASDAQ:CHRS) ("Coherus", "Coherus Oncology" or the "Company") today announced a special dividend of contingent value rights (each, a "CVR" and collectively, the
Benzinga · Aug 7, 2026
Guggenheim analyst Paul Jeng maintains Coherus Oncology (NASDAQ:CHRS) with a Buy and lowers the price target from $12 to $10.
SeekingAlpha · Aug 7, 2026
Coherus Oncology, Inc. (CHRS) Q2 2026 Earnings Call August 5, 2026 5:00 PM EDTCompany ParticipantsCarrie Graham - Vice President of Investor Relations &...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CHRS.
